Increased acetyl and total histone levels in post-mortem Alzheimer's disease brain

Neurobiology of Disease

Volumn 74, Issue , 2015, Pages 281-294

  Narayan, Pritika J ^a   Lill, Claire ^a   Faull, Richard ^a   Curtis, Maurice A ^a   Dragunow, Mike ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alzheimer's disease; Epigenetics; Histone acetylation; Histone deacetylase inhibitor; Histone H3; Histone H4; Protein degradation

Indexed keywords

ACETYL HISTONE H3; ACETYL HISTONE H4; AMYLOID BETA PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTONE H3; HISTONE H4; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; NUCLEAR PROTEIN; TAU PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; VALPROIC ACID; AMYLOID; HISTONE; MAPT PROTEIN, HUMAN; THIAZOLE DERIVATIVE; THIOFLAVINE;

ALZHEIMER DISEASE; ANTIBODY LABELING; ARTICLE; AUTOPSY; BRAIN LEVEL; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFERIOR TEMPORAL GYRUS; MALE; MIDDLE TEMPORAL GYRUS; NERVE CELL NECROSIS; NEUROBLASTOMA CELL LINE; NEUROPATHOLOGY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; SK N SH CELL LINE; TISSUE MICROARRAY; AGED; AMYLOID PLAQUE; BRAIN; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; AMYLOID; BLOTTING, WESTERN; BRAIN; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONES; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; TAU PROTEINS; THIAZOLES; TISSUE ARRAY ANALYSIS; UBIQUITIN;

EID: 84919335662     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.11.023     Document Type: Article

References (107)

1. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 2008, 8:57-64.
2. Bence N.F., et al. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
3. Bie B., et al. Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nat. Neurosci. 2014, 17:223-231.
4. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
5. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278.
6. Braak H., Braak E. Staging of Alzheimer-related cortical destruction. Int. Psychogeriatr. / IPA. 1997, 9:257-261.
7. Branca C., et al. Pharmacological targeting of the I 2-amyloid precursor protein intracellular domain. Sci. Rep. 2014, 4.
8. Buerger K., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002, 59:627-629.
9. Butner K.A., Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J. Cell Biol. 1991, 115:717-730.
10. Cao X., Sudhof T.C. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120.
11. Chen J.J., et al. Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein δ and CREB-binding protein. Mol. Biol. Cell 2005, 16:5579-5591.
12. Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
13. Coppieters N., et al. Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. Neurobiol. Aging 2014, 35:1334-1344.
14. Cosín-Tomás M., et al. Epigenetic alterations in hippocampus of SAMP8 senescent mice and modulation by voluntary physical exercise. Front. Aging Neurosci. 2014, 6.
15. Currie J.R., et al. Reduction of histone cytotoxicity by the Alzheimer [beta]-amyloid peptide precursor. Biochim. Biophys. Acta Mol. Cell Res. 1997, 1355:248-258.
16. De Boni U., Crapper McLachlan D.R. Senile dementia and Alzheimer's disease: A current view. Life Sci. 1980, 27:1-14.
17. Deal R.B., et al. Genome-wide kinetics of nucleosome turnover determined by metabolic labeling of histones. Science 2010, 328:1161-1164.
18. Dickson D.W., et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993, 7:75-83.
19. Ding Y., et al. Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces beta-secretase (BACE1) levels and Abeta generation. J. Biol. Chem. 2012, 287:8424-8433.
20. Drechsel D.N., et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3:1141-1154.
21. Fischer A., et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182.
22. Forester B., et al. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. Am. J. Geriatr. Pharmacother. 2007, 5:209-217.
23. Frost B., et al. Tau promotes neurodegeneration through global chromatin relaxation. Nat. Neurosci. 2014, 17:357-366.
24. Giannakopoulos P., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
25. Goedert M., et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4051-4055.
26. Goedert M., et al. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5066-5070.
27. Govindarajan N., et al. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 2012, 26:187-197.
28. Graff J., Mansuy I.M. Epigenetic codes in cognition and behaviour. Behav. Brain Res. 2008, 192:70-87.
29. Graff J., et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
30. Gregori L., et al. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 1995, 270:19702-19708.
31. Grober E., et al. Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 1999, 20:573-579.
32. Grundke-Iqbal I., et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261:6084-6089.
33. Grundke-Iqbal I., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
34. Gu X., et al. Oxidative stress induces DNA demethylation and histone acetylation in SH-SY5Y cells: potential epigenetic mechanisms in gene transcription in Abeta production. Neurobiol. Aging 2013, 34:1069-1079.
35. Guan J.S., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
36. Hampel H., et al. Value of CSF B-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 2004, 9:705-710.
37. Hendrickx A., et al. Epigenetic regulations of immediate early genes expression involved in memory formation by the amyloid precursor protein of alzheimer disease. PLoS One 2014, 9.
38. Henikoff S. Nucleosome destabilization in the epigenetic regulation of gene expression. Nat. Rev. Genet. 2008, 9:15-26.
39. Herrmann N. Valproic acid treatment of agitation in dementia. Can. J. Psychiatry 1998, 43:69-72.
40. Herrmann N., et al. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2007, 23:116-119.
41. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
42. Huang H.C., et al. Curcumin attenuates amyloid-beta-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3beta signaling pathway. J. Recept. Signal Transduct. Res. 2014, 34:26-37.
43. Ikura T., et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000, 102:463-473.
44. Irwin D.J., et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 2012, 135:807-818.
45. Kasckow J.W., et al. A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: Assessment with the BEHAVE-AD and CGI rating scales. Curr. Ther. Res. Clin. Exp. 1997, 58:981-989.
46. Kelly T.K., et al. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res. 2012, 22:2497-2506.
47. Kilgore M., et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
48. Kim H.S., et al. Inhibition of histone deacetylation enhances the neurotoxicity induced by the C-terminal fragments of amyloid precursor protein. J. Neurosci. Res. 2004, 75:117-124.
49. Kunik M.E., et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int. J. Geriatr. Psychiatry 1998, 13:29-34.
50. Langley B., et al. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:41-50.
51. Levenson J.M., Sweatt J.D. Epigenetic mechanisms in memory formation. Nat. Rev. Neurosci. 2005, 6:108-118.
52. Levenson J.M., et al. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 2004, 279:40545-40559.
53. Lewis P.N., et al. Changes in chromatin structure associated with Alzheimer's disease. J. Neurochem. 1981, 37:1193-1202.
54. Liang J., et al. Neonatal exposure to benzo[a]pyrene decreases the levels of serum testosterone and histone H3K14 acetylation of the StAR promoter in the testes of SD rats. Toxicology 2012, 302:285-291.
55. Lithner C.U., et al. Disruption of neocortical histone H3 homeostasis by soluble Abeta: implications for Alzheimer's disease. Neurobiol. Aging 2013, 34:2081-2090.
56. Lott A.D., et al. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J. Neuropsychiatry Clin. Neurosci. 1995, 7:314-319.
57. Loy R., Tariot P.N. Neuroprotective properties of valproate: potential benefit for AD and tauopathies. J. Mol. Neurosci. 2002, 19:303-307.
58. Lu X., et al. Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer's disease. PLoS One 2014, 9.
59. Lukiw W.J., Crapper McLachlan D.R. Chromatin structure and gene expression in Alzheimer's disease. Mol. Brain Res. 1990, 7:227-233.
60. Marks P.A., et al. Histone deacetylases. Curr. Opin. Pharmacol. 2003, 3:344-351.
61. Marques S.C., et al. Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience 2012, 220:256-266.
62. McFarland K.N., et al. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease. PLoS One 2012, 7.
63. McLachlan D.R.C., et al. Chromatin structure in scrapie and Alzheimer's disease. Can. J. Neurol. Sci. 1986, 13:427-431.
64. Mehler M.F., Mattick J.S. Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. Physiol. Rev. 2007, 87:799-823.
65. Michan S., et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J. Neurosci. 2010, 30:9695-9707.
66. Miller C.P., et al. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: A mechanism for synergy in leukemia cells. Blood 2009, 113:4289-4299.
67. Mirra S.S., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
68. Mori H., et al. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 1987, 235:1641-1644.
69. Morris J.C., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39:1159-1165.
70. Morris M.J., et al. Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain. Behav. Pharmacol. 2010, 21:409-419.
71. Narayan P.J., Dragunow M. High content analysis of histone acetylation in human cells and tissues. J. Neurosci. Methods 2010, 193:54-61.
72. Narayan M., Nelson J.C. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J. Clin. Psychiatry 1997, 58:351-354.
73. Norenberg M.D. Astrocyte responses to CNS injury. J. Neuropathol. Exp. Neurol. 1994, 53:213-220.
74. Page B., et al. A new fluorometric assay for cytotoxicity measurements in-vitro. Int. J. Oncol. 1993, 3:473-476.
75. Pemberton A.D., et al. Proteomic identification of interactions between histones and plasma proteins: Implications for cytoprotection. Proteomics 2010, 10:1484-1493.
76. Porsteinsson A.P. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006, 23:877-886.
77. Porsteinsson A.P., et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriatr. Psychiatry 2001, 9:58-66.
78. Porsteinsson A.P., et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 2003, 11:434-440.
79. Potempska A., et al. Interaction between the beta-amyloid peptide precursor and histones. Arch. Biochem. Biophys. 1993, 304:448-453.
80. Rao J.S., et al. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl. Psychiatry 2012, 2.
81. Ricobaraza A., et al. Phenylbutyrate ameliorates cognitive deficit and reduces Tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
82. Roth S.Y., et al. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
83. Rouaux C., et al. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem. Pharmacol. 2004, 68:1157-1164.
84. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
85. Scotter E.L., et al. High throughput quantification of mutant huntingtin aggregates. J. Neurosci. Methods 2008, 171:174-179.
86. Seo J., et al. Trichostatin A epigenetically increases calpastatin expression and inhibits calpain activity and calcium-induced SH-SY5Y neuronal cell toxicity. FEBS J. 2013, 280:6691-6701.
87. Serrano-Pozo A., et al. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am. J. Pathol. 2013, 182:2332-2344.
88. Siegmund K.D., et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2007, 2.
89. Sival R.C., et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized placebo controlled clinical trial. Int. J. Geriatr. Psychiatry 2002, 17:579-585.
90. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
91. Su J.H., et al. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994, 5:2529-2533.
92. Sugaya K., et al. Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus. Neurochem. Int. 1997, 31:275-281.
93. Sumioka A., et al. Role of 14-3-3gamma in FE65-dependent gene transactivation mediated by the amyloid beta-protein precursor cytoplasmic fragment. J. Biol. Chem. 2005, 280:42364-42374.
94. Taberlay P.C., et al. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 2014, 10.1101/gr.163485.113.
95. Tariot P.N., et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr. Ther. Res. Clin. Exp. 2001, 62:51-67.
96. Tariot P.N., et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: A randomized, controlled trial. Am. J. Geriatr. Psychiatr. 2005, 13:942-949.
97. Turner B.M. Cellular memory and the histone code. Cell 2002, 111:285-291.
98. Vecsey C.G., et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 2007, 27:6128-6140.
99. Waldvogel H.J., et al. Immunohistochemical staining of post-mortem adult human brain sections. Nat. Protoc. 2006, 1:2719-2732.
100. Waldvogel H.J., et al. The collection and processing of human brain tissue for research. Cell Tissue Bank. 2008, 9:169-179.
101. Wang X., et al. An effect of DNA sequence on nucleosome occupancy and removal. Nat. Struct. Mol. Biol. 2011, 18:507-509.
102. Wang J., et al. Epigenetic mechanisms linking diabetes and synaptic impairments. Diabetes 2014, 63:645-654.
103. Wang Z., et al. Valproic acid reduces neuritic plaque formation and improves learning deficits in APPSwe/PS1A246E transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin. CNS Neurosci. Ther. 2014, 20:209-217.
104. Wiley J.C., et al. Fe65 stimulates proteolytic liberation of the beta-amyloid precursor protein intracellular domain. J. Biol. Chem. 2007, 282:33313-33325.
105. Wood M.A., et al. A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn. Mem. 2006, 13:609-617.
106. Wu J., et al. Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. Neurobiol. Aging 2013, 34:2843-2852.
107. Zocchi L., Sassone-Corsi P. Joining the dots: From chromatin remodeling to neuronal plasticity. Curr. Opin. Neurobiol. 2010, 20:432-440.